NEW YORK (GenomeWeb) – Bruker reported after the close of the market Thursday that its first quarter revenues rose 12 percent year over year.

For the three months ended March 31, the firm said total revenues rose to $431.7 million from $384.9 million in the first quarter of 2017, beating analysts' consensus estimate of $417.4 million.

Bruker's organic revenue was up 4 percent year over year, while the favorable effect from changes in foreign currency rates was 8 percent, and growth from acquisitions was 1 percent.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.